Initial Statement of Beneficial Ownership (3)
May 21 2020 - 8:45AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Serafini-Lamanna Tony |
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/18/2020
|
3. Issuer Name and Ticker or Trading Symbol
MERIDIAN BIOSCIENCE INC [VIVO]
|
|
(Last)
(First)
(Middle)
3471 RIVER HILLS DRIVE |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Executive VP-Diagnostics / |
|
(Street)
CINCINNATI, OH 45244
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 21020 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | (1) | 4/30/2028 | Common Stock | 10000 | $14.60 | D | |
| Stock Option (Right to Buy) | (2) | 3/26/2030 | Common Stock | 4000 | $6.97 | D | |
| Explanation of Responses: |
| (1) | These non-qualified options were awarded under the 2012 Stock Incentive Plan and vest in full (100%) on 4/30/2022. |
| (2) | These non-qualified options were awarded under the 2012 Stock Incentive Plan and vest in full (100%) on 3/26/2023. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Serafini-Lamanna Tony
3471 RIVER HILLS DRIVE
CINCINNATI, OH 45244 |
|
| Executive VP-Diagnostics |
|
Signatures
|
| /s/ Bryan T. Baldasare, as Attorney-in-Fact for Tony Serafini-Lamanna | | 5/21/2020 |
| **Signature of Reporting Person | Date |
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Nov 2023 to Nov 2024
